LuLu Hypermarkets join in the National Day party

Faisal H. Al-Jarba cuts the 88-meter cake at Lulu Hypermarket’s newly opened outlet at Yarmouk, Riyadh.
Updated 25 September 2018

LuLu Hypermarkets join in the National Day party

A wide variety of social and cultural programs were arranged at all the LuLu Hypermarkets outlets across the Kingdom as part of the 88th National Day celebrations.
The grand inauguration of the National Day celebrations was held on Sunday at 9 p.m. at LuLu’s newly opened outlet in Atyaf Mall, Yarmouk. A massive 88-meter-long cake was cut, representing 88 years in the history of the Kingdom, in the esteemed presence of Faisal H. Al-Jarba, vice chairman of Nameyah International.
LuLu extended its National Day wishes to all Saudi Arabian citizens and also conveyed its gratitude to the rulers and people of the Kingdom for helping to make LuLu the largest hypermarket group in Saudi Arabia.
“We are pleased to offer a diverse collection of Saudi products at attractive prices. Because of our customer-friendly services throughout a decade, LuLu has become the ultimate spot for a memorable shopping experience with friends and family,” said Bashar Naser Al-Bashar, head of administration at LuLu Saudi Hypermarkets.
“This year our celebrations are the first of their kind and we are so much pleased to offer a diverse collection of locally grown fruits, vegetables, and other Saudi products at attractive prices," said Al-Bashar.


Clinical trials to accelerate adoption of new drug treatments in Saudi Arabia

Updated 27 May 2020

Clinical trials to accelerate adoption of new drug treatments in Saudi Arabia

  • Trials are being led locally as an essential means to verify the safety and effectiveness of a new drug
  • Eli Lilly has a major role to play during the coronavirus disease (COVID-19) pandemic

RIYADH: Clinical trials in Saudi Arabia could speed up the adoption of new drugs locally, a pharmaceutical executive has told Arab News.

“Clinical trials have two very big benefits for the Kingdom. Firstly, they provide data in the long run with respect to safety and efficacy, catered specifically to the Saudi population. Secondly, they impact local investment and build healthcare capabilities,” Managing Director of Eli Lilly Dimitri Livadas said..

Lividas further explained that the clinical trial phase of any new treatment is crucial as it represents the stage between the adoption or rejection of a drug. Working with the Ministry of Health and with a presence in the Kingdom for 42 years, the pharmaceutical company began research trials in the country in 2016, consisting of five pre-marketing activities and three monitoring studies for post-marketing.

Lividas added that the trials are being led locally as an essential means to verify the safety and effectiveness of a new drug before it is put to the market and introduced to patients. The majority of these are focused on diabetes, oncology, immunology, and osteoporosis.

“We genuinely believe that our future is here in Saudi Arabia. We continue to make great progress in having a commercial organization in the Kingdom that is fully staffed by Saudi nationals,” said Lividas.

As a biopharmaceutical company, Eli Lilly has a major role to play during the coronavirus disease (COVID-19) pandemic. It recently announced partnership with AbCellera to develop a treatment for the virus and aims to enter into clinical trials this year.

“I salute the Saudi authorities for their strong measures to contain the spread of COVID-19. I think it is an example to the world on how to do this. I would like to also express my gratitude toward all healthcare professionals who are currently on the frontlines, risking their own health to help others," Lividas said.